Cytek Biosciences, Inc. (CTKB) Financial Statements
Industry: Laboratory Analytical Instruments
In fiscal 2025, Cytek Biosciences reported revenue of $201.5M, up 0.5% from $200.5M the year before. Net income was -$66.5M (a -33.0% net margin), or -$0.52 per diluted share. Gross margin was 51.8% and operating margin was -20.0%. Operating activities generated -$4.7M of cash, leaving -$8.8M of free cash flow. At fiscal year end, Cytek Biosciences held $461.5M in total assets against $119.8M in total liabilities, including $90.9M of cash and equivalents.
Open the full interactive Cytek Biosciences financials → Quarterly statements, key ratios, valuation history and price charts.
Cytek Biosciences Key Stats
| Share Price | $5.35 |
|---|---|
| Market Cap | $692.6M |
| Revenue YoY Growth | +0.5% |
| 52-Week Range | $3.36 – $6.09 |
| Shares Outstanding | 129.5 million (basic, 2026 Q2) |
Cytek Biosciences Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $128.0M | $164.0M | $193.0M | $200.5M | $201.5M |
| Cost of Goods Sold | $48.8M | $63.1M | $83.6M | $89.3M | $97.0M |
| Gross Profit | $79.1M | $101.0M | $109.4M | $111.1M | $104.5M |
| Operating Income | $9.2M | -$1.8M | -$27.8M | -$20.5M | -$40.4M |
| Pre-Tax Income | $5.9M | $1.3M | -$15.7M | -$5.7M | -$29.8M |
| Income Tax | $2.9M | -$1.2M | -$3.6M | $320,000 | $36.7M |
| Net Income | $3.0M | $2.5M | -$12.1M | -$6.0M | -$66.5M |
| Diluted EPS | — | $0.02 | -$0.09 | -$0.05 | -$0.52 |
Cytek Biosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $52.3M | $62.1M | $44.1M | $48.1M |
| Net Income | -$5.5M | -$44.1M | -$18.9M | -$12.2M |
| Diluted EPS | -$0.04 | -$0.35 | -$0.15 | -$0.09 |
Cytek Biosciences Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $364.6M | $296.6M | $167.3M | $98.7M | $90.9M |
| Current Assets | $431.7M | $454.0M | $392.1M | $396.4M | $392.0M |
| Total Assets | $463.3M | $519.5M | $494.5M | $499.5M | $461.5M |
| Current Liabilities | $33.2M | $49.0M | $56.2M | $67.7M | $77.8M |
| Total Liabilities | $57.9M | $93.9M | $101.4M | $103.8M | $119.8M |
| Shareholders' Equity | $405.4M | $425.5M | $393.1M | $395.7M | $341.7M |
Cytek Biosciences Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | $4.6M | -$12.2M | $5.3M | $25.4M | -$4.7M |
| Cash From Investing | -$21.0M | -$55.9M | -$93.9M | -$83.0M | $10.1M |
| Cash From Financing | $213.6M | $5.5M | -$41.8M | -$15.8M | -$13.4M |
| Free Cash Flow | $266,000 | -$22.0M | $633,000 | $21.9M | -$8.8M |
Figures from Cytek Biosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cytek Biosciences financials page for every line item.
Cytek Biosciences Company Profile
| Ticker | CTKB |
|---|---|
| Exchange | Nasdaq |
| Industry | Laboratory Analytical Instruments |
| Headquarters | Fremont, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001831915 |
Frequently Asked Questions
What was Cytek Biosciences' revenue in fiscal 2025?
Cytek Biosciences (CTKB) reported revenue of $201.5M for fiscal 2025.
What is Cytek Biosciences' annual revenue history?
Cytek Biosciences' annual revenue by fiscal year: 2021: $128.0M; 2022: $164.0M; 2023: $193.0M; 2024: $200.5M; 2025: $201.5M.
What was Cytek Biosciences' net income in fiscal 2025?
Cytek Biosciences reported net income of -$66.5M for fiscal 2025.
What was Cytek Biosciences' earnings per share (EPS) in fiscal 2025?
Cytek Biosciences' diluted EPS was -$0.52 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cytek Biosciences generate in fiscal 2025?
Cytek Biosciences generated -$8.8M of free cash flow in fiscal 2025.
What was Cytek Biosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), Cytek Biosciences reported revenue of $48.1M.
How many shares of Cytek Biosciences are outstanding?
Cytek Biosciences reported a weighted average of 129.5 million basic shares outstanding in 2026 Q2.
What is Cytek Biosciences' market cap?
Based on its latest closing price, Cytek Biosciences (CTKB) has a market capitalization of about $692.6M.
When does Cytek Biosciences' fiscal year end?
Cytek Biosciences' fiscal year end, as registered with the SEC, is December 31.
Where is Cytek Biosciences headquartered?
Cytek Biosciences lists its business address in Fremont, California in its SEC filings.